Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
ZNTL

Zentalis Pharmaceuticals Inc (ZNTL)

$27.140.74%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$26.305
Day's Range
$27.44
$17.33
52-Week Range
$87.19
1 month return12.57%
3 month return41.73%
1 year return42.05%
5 year return16.98%

Company Information

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.
OrganizationZentalis Pharmaceuticals Inc
Employees124
CEO
IndustryHealth Technology

Analyst Recommendation

based on 15 analysts ratings

Buy
93%
Buy
6%
Hold
0%
Sell

Based on 15 Wall street analysts offering stock ratings for Zentalis Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 261.09%

Current

$27.14

Target

$98.0

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
14
14
14
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.1B
Book Value
8.0
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-3.72
Wall Street Target Price
85.7

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
0.0
Price/Book (mrq)
2.82
Enterprise Value
732.1M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
0.0

Technicals

Beta
2.28
50 Day MA
42.14
200 Day MA
60.86

Institutional Holdings

FMR Inc

11.84%

Matrix Capital Management Company, LLC

7.64%

T. Rowe Price Associates, Inc.

7.37%

Vanguard Group Inc

5.69%

Avidity Partners Management LP

5.58%

BlackRock Inc

4.99%

Discover more

Frequently Asked Questions

What is Zentalis Pharmaceuticals Inc share price today?

Can Indians buy Zentalis Pharmaceuticals Inc shares?

How can I buy Zentalis Pharmaceuticals Inc shares from India?

Can Fractional shares of Zentalis Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Zentalis Pharmaceuticals Inc stocks?

What are today’s High and Low prices of Zentalis Pharmaceuticals Inc?

What are today’s traded volumes of Zentalis Pharmaceuticals Inc?

What is today’s market capitalisation of Zentalis Pharmaceuticals Inc?

What is the 52 Week High and Low Range of Zentalis Pharmaceuticals Inc?

How much percentage Zentalis Pharmaceuticals Inc is down from its 52 Week High?

How much percentage Zentalis Pharmaceuticals Inc is up from its 52 Week low?

What are the historical returns of Zentalis Pharmaceuticals Inc?

Who is the Chief Executive Officer (CEO) of Zentalis Pharmaceuticals Inc?